doi:10.3969/j.issn.1004-583X.2021.08.018

Abstract

CLC Number:

R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.08.018

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I8/761

References 28

[1]	Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen[J]. N Engl J Med, 2000, 343(4):230-238. doi: 10.1056/NEJM200007273430401 URL
[2]	Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia[J]. Diabetes Care, 2016, 39(7):1230-1240. doi: 10.2337/dc15-1988 URL
[3]	Lablanche S, Vantyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): A ulticentre, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2018, 6(7):527-537. doi: 10.1016/S2213-8587(18)30078-0 URL
[4]	Rickels MR, Peleckis AJ, Markmann E, et al. Long-term improvement in glucose control and counterregulation by islet transplantation for type 1 diabetes[J]. J Clin Endocrinol Metab, 2016, 101(11):4421-4430. doi: 10.1210/jc.2016-1649 URL
[5]	胡安斌, 凌象超, 段金良, 等. 同种异体胰岛移植治疗成人晚期糖尿病早期疗效观察[J]. 中华医学杂志, 2020, 100(26):2040-2043.
[6]	Fensom B, Harris C, Thompson SE, et al. Islet cell transplantation improves nerve conduction velocity in type 1 diabetes compared with intensive medical therapy over six years[J]. Diabetes Res Clin Pract, 2016, 122:101-105. doi: 10.1016/j.diabres.2016.10.011 URL
[7]	Holmes-Walker DJ, Gunton JE, Hawthorne W, et al. Islet transplantation provides superior glycemic control with less hypoglycemia compared with continuous subcutaneous insulin infusion or multiple daily insulin injections[J]. Transplantation, 2017, 101(6):1268-1275. doi: 10.1097/TP.0000000000001381 pmid: 27490410
[8]	Kumar AF, Gruessner RW, Seaquist ER. Risk of glucose intolerance and diabetes in hemipancreatectomized donors selected for normal preoperative glucose metabolism[J]. Diabetes Care, 2008, 31(8):1639-1643. doi: 10.2337/dc07-2453 URL
[9]	Ricordi C, Goldstein JS, Balamurugan AN, et al. National Institutes of Health-sponsored Clinical Islet Transplantation Consortium phase 3 trial: Manufacture of a complex cellular product at eight processing facilities[J]. Diabetes, 2016, 65(11):3418-3428. doi: 10.2337/db16-0234 URL
[10]	张博雅, 张静楠, 裴广辉, 等. 门静脉内胰岛移植对受者转氨酶水平的影响因素分析[J]. 中华器官移植杂志. 2019, 40(9):519-522.
[11]	Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes[J]. JAMA, 2005, 293(7): 830, 835.
[12]	Estrada EJ, Decima JL, Bortman G, et al. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial[J]. Cell Transplant, 2019, 28(12):1632-1640. doi: 10.1177/0963689719883813 URL
[13]	Ye L, Li L, Wan B, et al. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus[J]. Stem Cell Res Ther, 2017, 8(1):90-95. doi: 10.1186/s13287-017-0542-1 URL
[14]	Nijhoff MF, Engelse MA, Dubbeld J, et al. Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression[J]. Am J Transplant, 2016, 16(1):246-253. doi: 10.1111/ajt.13425 pmid: 26288226
[15]	Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: Clinical and immunological follow-up after 7 years from diagnosis[J]. Diabetologia, 2019, 62(4):655-664. doi: 10.1007/s00125-018-4786-9 pmid: 30569273
[16]	Takita M, Matsumoto S, Shimoda M, et al. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation[J]. Clin Transplant, 2012, 26(5):471-484.
[17]	Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation[J]. PLoS One, 2008, 3(6):e2435. doi: 10.1371/journal.pone.0002435 URL
[18]	Pepper AR, Bruni A, Pawlick R, et al. Post-transplant characterization of long-term functional hESC-derived pancreatic endoderm grafts[J]. Diabetes, 2019, 68(5):953-962. doi: 10.2337/db18-0788 URL
[19]	焦自钊, 薛武军, 安茂竹, 等. 联合移植的脂肪间充质干细胞对胰岛移植物功能及生存的影响[J]. 中华器官移植杂志, 2019, 4(7): 428, 433.
[20]	Millman JR, Xie C, Van Dervort A, et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes[J]. Nat Commun, 2016, 7:11463. doi: 10.1038/ncomms11463. doi: 10.1038/ncomms11463 URL
[21]	Sui L, Danzl N, Campbell SR, et al. β-Cell replacement in mice using human type 1 diabetes nuclear transfer embryonic stem cells[J]. Diabetes, 2018, 67(1):26-35. doi: 10.2337/db17-0120 URL
[22]	Salama BF, Seeberger KL, Korbutt GS. Fibrin supports subcutaneous neonatal porcine islet transplantation without the need for pre-vascularization[J]. Xenotransplantation, 2020, 27(4):e12575.
[23]	程宇, 周丁华, 闫涛, 等. 大鼠肠系膜与肾被膜下移植胰岛治疗糖尿病的疗效对比[J]. 暨南大学学报. 2019, 40(2):157-164.
[24]	刘国涛, 郭栋, 刘全达, 等. 胃浆膜下层与门静脉胰岛移植治疗糖尿病大鼠的实验研究[J]. 中国现代医学杂志, 2018, 28(11):5-9.
[25]	Pellegrini S, Cantarelli E, Citro A, et al. Selective local irradiation mproves islet engraftment and survival in intra-bone marrow islet transplantation[J]. Cytotherapy, 2019, 21(10):1025-1032. doi: S1465-3249(19)30821-7 pmid: 31444049
[26]	Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade[J]. Transplantation, 2010, 90(12):1595-1601. doi: 10.1097/TP.0b013e3181fe1377 pmid: 20978464
[27]	Ludwig B, Ludwig S, Steffen A, et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes[J]. Proc Natl Acad Sci USA, 2017, 114(44):11745-11750. doi: 10.1073/pnas.1708420114 URL
[28]	李传贵, 宋亚军, 杨加彩, 等. 探讨γδT细胞在小鼠胰岛移植排斥反应中的作用[J]. 重庆医学, 2018, 47(13):1705-1708.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lv Shasha, Song Jinlan, Shi Jian. Mitochondrial mutation m.3243A> G associated with diabetes mellitus: One case report and literature review [J]. Clinical Focus, 2024, 39(2): 160-163.
[2]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[3]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[4]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[5]	Yang Xin, Xu Huajiao. Bibliometric analysis of literatures reporting psychological intervention of patients with diabetes mellitus: Based on Web of Science [J]. Clinical Focus, 2023, 38(8): 731-736.
[6]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[7]	Wu Yanan, Yan Tianmei, Liang Peng, Wei Limin. High-risk identification of depressive symptoms in middle-elderly patients with diabetes [J]. Clinical Focus, 2023, 38(6): 516-520.
[8]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.
[9]	Rao Xiaojuan, Shi Shuangwei, Sang Yanhong. Comparison of short-term efficacy of insulin degludec/insulin versus continuous subcutaneous infusion of insulin asparton diabetic patients admitted in non-endocrinology departments [J]. Clinical Focus, 2023, 38(2): 132-136.
[10]	Xie Feifei, Zhang Weijian. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(1): 20-36.
[11]	Wang Cui, Lin Hao, Wu Pingping, Zhang Yali, Ren Jian, Xu Ting, Dong Guoyu, Zai Guotian. Correlation between hyperhomocysteinemia and early renal disease in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(1): 42-45.
[12]	. [J]. Clinical Focus, 2023, 38(1): 79-83.
[13]	Wang Runqing, Wang Qian, Liao Jianxiong. A network meta-analysis of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes [J]. Clinical Focus, 2022, 37(12): 1061-1073.
[14]	Wang Wenqi, Zhang Tao. Effect of semaglutide on total myocardial ischemic burden and serum inflammatory factors in patients with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2022, 37(11): 996-1000.
[15]	. [J]. Clinical Focus, 2022, 37(10): 953-956.